Vitamin D treatment in hemodialysis patients with low serum levels of parathyroid hormone: Which is the best choice?

Journal of Nephrology

Volumn 23, Issue 2, 2010, Pages 210-215

  Lomonte, Carlo ^a   Casucci, Francesco ^a   Libutti, Pasquale ^a   Losurdo, Nicola ^a   Teutonico, Annalisa ^a   Basile, Carlo ^a  

^a MIULLI GENERAL HOSPITAL   (Italy)

Author keywords

Calcidiol; Calcitriol; Hemodialysis; Hypoparathyroidism; Parathyroid hormone

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER;

ADULT; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPOPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; CALCIFEDIOL; CALCITRIOL; CALCIUM; DOWN-REGULATION; FEMALE; HUMANS; HYPOPARATHYROIDISM; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PATIENT SELECTION; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMINS;

EID: 77749258176     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl. 2002;(80):155-160.
2. Drüeke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant. 2007;22:1828-1839.
3. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8-F28.
4. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575-580.
5. Brown EM, Mac Leod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81:239-297.
6. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33-43.
7. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115-1125.
8. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73:1345-1354.
9. Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant. 2008;23:3050-3052.
10. Frazão JM, Martins P. Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens. 2009;18:303-307.
11. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis Suppl. 2003;42:S1-S201.
12. Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 2005;67:1120-1125.
13. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446-456.
14. Del Valle E, Negri AL, Aguirre C, et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11:315-321.
15. 3 in northern-dwelling patients with chronic kidney disease. J Nephrol. 2009;22:75-82.
16. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem. 2004;279:16754-16766.
17. 3 enhance human osteoblast differentiation and mineralization. J Cell Biochem. 2006;99:922-935.
18. Morosetti M, Jancovic L, Palombo G, et al. High-dose calcitriol therapy and progression of cardiac vascular calcifications. J Nephrol. 2008;21:603-608.
19. Coen G. Calcimimetics, parathyroid hormone, and vascular calcification in chronic kidney disease. Kidney Int. 2008;74:1229-1231.
20. Dusso A, Brown AJ. Mechanism of vitamin D action and its regulation. Am J Kidney Dis. 1998;32(Suppl 2):S13-S24.
21. Kokuho T, Toya Y, Kawaguchi Y, et al. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels. Ther Apher Dial. 2007;11:442-448.
22. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994;46:1160-1166.
23. Taniguchi M, Tokumoto M, Tsuruya K, et al. Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant. 2008;23:3662-3669.
24. Jean G, Terrat JC, Vanel T, et al. Daily oral 25-hydroxychole-calciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant. 2008;23:3670-3676.
25. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004-1013.